Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease Steven M Keller, MD, Mark G Vangel, PhD, Henry Wagner,

Slides:

Advertisements

Similar presentations

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution Linda W. Martin, MD, Arlene.

Advertisements

Stephen R. Broderick, MD, MPHS

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Circulating tumor DNA: Solid data from liquid biopsies

Survival after resection of synchronous non–small cell lung cancer

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Sleeve lung resection for lung cancer: Analysis according to the type of procedure Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

How should we treat air leaks?

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

The lord of the rings Antonio Miceli, MD, PhD

EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer Sarita Dubey, MD, Patricia Stephenson, ScD, Donna E. Levy,

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Lung adenocarcinoma: Are skip N2 metastases different from non-skip?

Yang Zhang, MD, Haiquan Chen, MD, PhD

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

A first start for lung transplantation?

Is surgery for multiple lung metastases reasonable

Stephen R. Broderick, MD, MPHS

Navigating the lung for hidden treasure

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

A fate worse than death Jennifer S. Lawton, MD

Attachment disorder in thoracoabdominal surgery

The Ross procedure: Time to reevaluate the guidelines

Manuel J. Antunes, MD, PhD, DSc

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Pulmonary Resection for Metastases from Colorectal Cancer

The harder one looks, the more one finds

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Percutaneous radiofrequency ablation of clinical stage I non–small cell lung cancer Takao Hiraki, MD, Hideo Gobara, MD, Hidefumi Mimura, MD, Yusuke Matsui,

Multifocal lung cancer within ground glass lesions: Are favorable outcomes consequent to surgical resection or inherent to the disease? Mara B. Antonoff,

Sebastien Gilbert, MD, Andre B. Martel, BSc, Andrew J

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Keep it short and sweet Ian A. Makey, MD, Scott B. Johnson, MD

The future of cardiac surgery training: A survival guide

The patent internal thoracic artery graft: Increased degree of difficulty for left-sided pulmonary resections Robbin G. Cohen, MD, MMM The Journal of.

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Karin M. Dunst, MD, Ludwig C. Mueller, MD

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Aritoshi Hattori, MD, Kenji Suzuki, MD

The Development of an International Registry

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node- negative T3 and T4 non–small cell lung cancer Benedict D.T. Daly, MD,

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease Steven M Keller, MD, Mark G Vangel, PhD, Henry Wagner, MD, Joan H Schiller, MD, Arnold Herskovic, MD, Ritsuko Komaki, MD, Randolph S Marks, MD, Michael C Perry, MD, Robert B Livingston, MD, David H Johnson, MD The Journal of Thoracic and Cardiovascular Surgery Volume 128, Issue 1, Pages 130-137 (July 2004) DOI: 10.1016/j.jtcvs.2003.11.061

Figure 1 Median survival was 65.4 months (95% CI, 45-88.8 months) for patients with N1 disease and 30.6 months (95% CI, 22.3-38.6 months) for all patients with N2 disease; 5-year survivals were 52% and 32%, respectively. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)

Figure 2 Median survival was 51.4 months (95% CI, 22.3 months–not reached) for patients with left upper lobe tumors and single-level N2 metastases and 49.4 months (95% CI, 25.4-89 months) for patients with left upper lobe tumors and N1 disease; 5-year survival was 42% in both groups. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)

Figure 3 Median survival was 20 months (95% CI, 14.3-53.4 months) for patients with multi-level N2 disease and 35.3 months (95% CI, 26.9-39.9 months) for patients with single-level N2 disease. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)

Figure 4 Median survival was 51.4 months (95% CI, 22.3 months–not reached) for patients with left upper lobe tumors and single-level N2 metastases and 18.2 months (95% CI, 7.6 months–not reached) for patients with multiple-level N2 disease. The difference approximated statistical significance. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)

Figure 5 Median survival was 58.8 months (95% CI, 35.5-106.7 months) for patients with solitary N2 skip metastases compared with 25.6 months (95% CI, 16.2-35.9 months) for patients with concomitant N1 and N2 disease; 5-year survivals were 50% and 18%, respectively. The Journal of Thoracic and Cardiovascular Surgery 2004 128, 130-137DOI: (10.1016/j.jtcvs.2003.11.061)